NCT07504523 — Ying Yuan, MD cancer immunotherapy trial
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
Registry record
| Registry ID | NCT07504523 ↗ |
|---|---|
| Lead sponsor | Ying Yuan, MD |
| Collaborators | Hangzhou Neoantigen Therapeutics Co., Ltd. |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Metastatic Colorectal Cancer (CRC) |
| Enrollment | 20 participants (target) |
| Start date | 2023-11-01 |
| Primary completion | 2027-12-31 (est.) |
| Last registry update | 1 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07504523), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07504523?
NCT07504523 (Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Ying Yuan, MD.
Is NCT07504523 recruiting?
As of the 2026-04-01 registry update, NCT07504523 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07504523?
The lead sponsor is Ying Yuan, MD. Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd..
What condition does NCT07504523 study?
The registered condition is Metastatic Colorectal Cancer (CRC). Primary completion is listed as 2027-12-31 (estimated).
Are results available for NCT07504523?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07504523.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.